Tag Archives: Biosimilar Development

European Introduction of Denosumab Biosimilars Strengthens Fresenius Kabi’s Position in Affordable Oncology and Osteoporosis Care

(IN BRIEF) Fresenius Kabi has launched its denosumab biosimilars Conexxence® and Bomyntra® across Europe following European Commission approval in July 2025 for all indications of their reference medicines Prolia® and Xgeva®. The products target a range of conditions including osteoporosis, … Read the full press release

Expanded Partnership Between Just – Evotec Biologics and Sandoz Enhances Biosimilar Development and Supply Security

(IN BRIEF) Just – Evotec Biologics and Sandoz have expanded their strategic partnership to advance the development and commercial manufacturing of biosimilars. This enhanced collaboration includes additional biosimilars in Sandoz’s pipeline and ensures long-term supply through Just – Evotec Biologics’ … Read the full press release